In this review we will focus on the variety of ways in which Rho signaling has been shown to be disrupted in cancer: alterations in protein levels of the GTPases, disruption to regulators of GTPases, changes in post-translational modifications of GTPases and finally we review the emerging literature on direct mutation of GTPases. Here, RHO is linked to cancer.